Back to School: How biopharma can reboot drug development. Access exclusive analysis here

INCB024360: Additional Phase I data

Additional data from an open-label, dose-escalation, U.S. Phase I trial in 52 patients showed that INCB024360 was well tolerated at doses of up

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE